Literature DB >> 23242280

Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases.

Kunikazu Tanji1, Atsushi Maruyama, Saori Odagiri, Fumiaki Mori, Ken Itoh, Akiyoshi Kakita, Hitoshi Takahashi, Koichi Wakabayashi.   

Abstract

Oxidative stress has been proposed as a potential mechanism for neurodegenerative diseases, such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS). In response to oxidative stress, the levels of numerous cytoprotective products are increased via alteration of the Kelch-like ECH-associated protein 1 (Keap1) and NF-E2-related factor 2 (Nrf2) system. One of the Nrf2 targets, p62, has been known to be incorporated into a wide spectrum of cytoplasmic inclusions in neurodegenerative diseases and interact with Keap1. However, it remains unclear whether Keap1 is associated with the pathogenesis of neurodegenerative diseases. In this study, we investigated the relationship between p62 and Keap1 in the brains of patients with AD, PD, dementia with Lewy bodies (DLB), and ALS. Biochemical analyses showed that p62 and Keap1 interacted with each other in AD and DLB brains and were extracted into similar detergent-soluble and -insoluble fractions. Pathologic examination demonstrated that anti-Keap1 antibodies immunostained Lewy bodies in PD and DLB, neurofibrillary tangles in AD, and skeinlike inclusions in ALS. Further analysis showed that the levels of common Nrf2 target genes were increased in AD compared with those in controls. However, there were no statistical significances in the levels of Nrf2 target genes in DLB relative to controls. Our pathologic and biochemical results suggest a molecular basis for stress response to be involved in the formation of cytoplasmic inclusions observed in several neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23242280     DOI: 10.1097/NEN.0b013e31827b5713

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  32 in total

1.  Non-canonical activation of NRF2: New insights and its relevance to disease.

Authors:  Matthew Dodson; Donna D Zhang
Journal:  Curr Pathobiol Rep       Date:  2017-04-19

2.  RBM45 Modulates the Antioxidant Response in Amyotrophic Lateral Sclerosis through Interactions with KEAP1.

Authors:  Nadine Bakkar; Arianna Kousari; Tina Kovalik; Yang Li; Robert Bowser
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

Review 3.  Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases.

Authors:  Yang Sun; Tuo Yang; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

4.  Increased Alzheimer's disease-like pathology in the APP/ PS1ΔE9 mouse model lacking Nrf2 through modulation of autophagy.

Authors:  Gururaj Joshi; Kok Ann Gan; Delinda A Johnson; Jeffrey A Johnson
Journal:  Neurobiol Aging       Date:  2014-09-06       Impact factor: 4.673

Review 5.  Redox-based therapeutics in neurodegenerative disease.

Authors:  G J McBean; M G López; F K Wallner
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

Review 6.  Therapeutic Approaches to Alzheimer's Disease Through Modulation of NRF2.

Authors:  Gahee Bahn; Dong-Gyu Jo
Journal:  Neuromolecular Med       Date:  2019-01-07       Impact factor: 3.843

Review 7.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

8.  Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning.

Authors:  Andrew J Levine; Steve Horvath; Eric N Miller; Elyse J Singer; Paul Shapshak; Gayle C Baldwin; Otoniel Martínez-Maza; Mallory D Witt; Peter Langfelder
Journal:  J Neuroimmunol       Date:  2013-09-26       Impact factor: 3.478

Review 9.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

Review 10.  The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?

Authors:  Kevin R Doty; Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  Brain Res       Date:  2014-09-08       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.